Clinical trial
Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic…
NCT00131742 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00131742 |
|---|---|
| Title | Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B |
| Official title | A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | telbivudine, lamivudine |
| Start date | Jul 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Aug 19, 2005 |
| Last update posted | May 12, 2015 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: